Hexarelin Mechanism of Action
Part of the full Hexarelin guide - a growth-hormone-releasing peptide reference compound, identity-verified with a COA on every vial.
In brief
Hexarelin is a synthetic hexapeptide growth-hormone-releasing peptide (GHRP) studied in vitro as an agonist of the growth-hormone-secretagogue receptor 1a (GHS-R1a), the same receptor engaged by the endogenous ligand ghrelin. The receptor-signaling description below is drawn entirely from in-vitro and ex-vivo pharmacology in the source entry; no therapeutic or human-use claim is made.
The detail
A closer look
01
GHS-R1a coupling through Gq/11 and phospholipase C
In pituitary somatotroph models, hexarelin is described as activating GHS-R1a, a G-protein-coupled receptor that couples through the Gq/11 family to phospholipase C (PLC). PLC activation hydrolyzes membrane phosphoinositides to generate two second messengers: inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). This is the canonical Gq/PLC branch, and in the source data it is the defined route by which hexarelin's receptor engagement is propagated into the cell.
02
IP3-driven calcium mobilization and PKC engagement
The two PLC products act on parallel arms. IP3 mobilizes calcium from intracellular stores, raising cytosolic Ca2+, while DAG (together with the rising calcium) engages protein kinase C (PKC). The entry specifies this IP3/DAG to intracellular-calcium/PKC cascade as the signal-transduction signature observed in pituitary somatotroph models - a phospholipid- and calcium-centric mechanism rather than a cyclic-nucleotide one.
03
Distinct from GHRH-receptor cAMP signaling
The source explicitly contrasts this pathway with GHRH-receptor signaling, which operates through cyclic AMP (cAMP). Hexarelin's GHS-R1a/Gq/11/PLC/IP3/PKC/Ca route is therefore described as mechanistically distinct from the cAMP-based GHRH axis. This distinction is the basis for treating GHRPs and GHRH-type peptides as separate receptor-pharmacology categories in the comparative literature referenced in the entry.
04
A second binding target: CD36 in cardiovascular-tissue models
Beyond the pituitary, the entry notes that hexarelin is also studied for binding the scavenger receptor CD36 in cardiovascular-tissue models. CD36 is a separate receptor target from GHS-R1a, giving hexarelin two documented binding interactions in the source data. All CD36 description is framed as in-vitro / ex-vivo receptor binding in tissue models, with no functional, therapeutic, or disease claim attached.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Hexarelin is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.